We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 507

Biotech secures $5.3 million for immunosuppressant drug research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 18 2013

San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as

Cancer biotech seeks $69 million in IPO

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 9 2014

Dicerna Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission indicating its intent to raise up

Federal Circuit dubbed a “rogue appeals court,” seen as biased in favor of patent holders

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

Writing for Ars Technica in an article titled “How a rogue appeals court wrecked the patent system,” associate writer Timothy Lee explores the history of the Federal Circuit Court of Appeals, noting that it was created in 1982 due to “concerns about the lack of uniformity in patent law that had become widespread.” With sole appellate jurisdiction over patent disputes, the court accomplished congressional goals by making patent law more uniform, but it had other side effects, according to Lee

House bill aims to increase FDA oversight of drug compounding pharmacies

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 26 2013

Joining bills already pending before the U.S. House and Senate, the Compounding Clarity Act of 2013 (H.R. 3089) would strengthen the Food and Drug

Federal Courts of Appeals conflict over validity of pay-for-delay deals

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 2 2012

The Third Circuit Court of Appeals issued a ruling in mid-July that found “any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market must be treated by a factfinder as prima facie evidence of an unreasonable restraint of trade,” thus supporting the Federal Trade Commission’s (FTC’s) view that pay-for-delay deals that settle patent disputes between name-brand pharmaceutical companies and their generic drug competitors violate antitrust law

WSJ says venture capital tougher to find for biotech companies

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 29 2012

Noting that venture capitalists invested just $3.92 billion in biotech companies in 2011, down from the $6.17 billion watermark in 2007, and that shares in biotechs that went public last year averaged nearly 30 percent less than their anticipated midpoint offering price, a recent Wall Street Journal article warns biotechs, “The gravy days are over”

Class action filed against 23andMe, Inc. over efficacy of home DNA test kits

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 30 2014

A New Mexico resident has filed a putative nationwide class action against 23andMe, Inc., alleging that claims for its DNA Collection Kits&mdash

FDA issues report to Congress on drug shortage mitigation, GAO weighs in

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • February 13 2014

In its first annual report to Congress on drug shortages for calendar year 2013, the U.S. Food and Drug Administration (FDA) has provided data

U.S. Senators propose subjecting compounded drugs to federal regulation

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 2 2013

Bipartisan Senate health committee leaders have released draft legislation that would give the Food and Drug Administration (FDA) greater oversight

Texas compounder agrees to nationwide recall of all sterile products

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 15 2013

According to the U.S. Food and Drug Administration (FDA), Cedar Park, Texas-based compounding pharmacy Specialty Compounding LLC has agreed to recall